ALFA Finder| Revenue growth | 21% YoY for FY26; 20% YoY for Q4 FY26. |
|---|---|
| Margins | Gross margins improved to 74.7%; EBITDA margins steady at 34%. |
| Demand visibility | Strong, backed by 10,800 active franchisees and new specialty segments. |
| Management confidence | High, revising growth guidance marginally upwards to mid-to-high teens. |
Growth
FY26 consolidated revenue grew 21% to ₹829cr; EBITDA rose 38% to ₹262cr; PAT jumped 81% to ₹163cr.
Outlook
Guidance revised to mid-to-high teens growth; venturing into genomics and allied diagnostic consumables.
Risks
Potential reagent price hikes due to geopolitical tensions and Middle East supply chain disruptions.
Earnings Call filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹490.80
- Market cap
- ₹7,821 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 54.2×Sector 54.5×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Other Announcement
Designated person Rahul Guha bought 2,121 Thyrocare shares via market purchase on November 6, 2026, worth ₹0.10 Crore. Post-trade holding is 200,859 shares.
- Value
- ₹0.10 Cr
Thyrocare Technologies Employee Stock Options
Thyrocare allotted 1,94,289 equity shares under its Employee Stock Option Scheme. The allotment lifts paid-up capital to Rs 159.36 crore.
Thyrocare Technologies Management Change
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare Technologies Other Announcement
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
- Value
- ₹0.11 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
- Value
- ₹141.4 Cr
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.